2023 Neurocritical Care Updates in Cerebrovascular Disease

HomeStrokeVol. 54, No. 102023 Neurocritical Care Updates in Cerebrovascular Disease No AccessArticle CommentaryRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessArticle CommentaryRequest AccessFull Text2023 Neurocritical Care Updates in Cerebrovascular Disease Ruchira M. Jha and Kevin N. Sheth Ruchira M. JhaRuchira M. Jha Correspondence to: Ruchira M. Jha, MD, MSc, Barrow Neurological Institute, 240 W Thomas Rd, Phoenix, AZ 85013. Email E-mail Address: [email protected]; E-mail Address: [email protected] https://orcid.org/0000-0002-3047-7649 Departments of Neurology and Neurosurgery, Barrow Neurological Institute, Phoenix, AZ (R.M.J.). and Kevin N. ShethKevin N. Sheth https://orcid.org/0000-0003-2003-5473 Departments of Neurology and Neurosurgery, Yale School of Medicine, Yale Center for Brain & Mind Health, New Haven, CT (K.N.S.). Originally published25 Sep 2023https://doi.org/10.1161/STROKEAHA.123.043018Stroke. 2023;54:2671–2675FootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.For Sources of Funding and Disclosures, see page 2674.Correspondence to: Ruchira M. Jha, MD, MSc, Barrow Neurological Institute, 240 W Thomas Rd, Phoenix, AZ 85013. Email ruchira.jha@barrowneuro.org; ruchirajha@gmail.comREFERENCES1. Sarraj A, Hassan AE, Abraham MG, Ortega-Gutierrez S, Kasner SE, Hussain MS, Chen M, Blackburn S, Sitton CW, Churilov L, et al; SELECT2 Investigators. Trial of endovascular thrombectomy for large ischemic strokes.N Engl J Med. 2023; 388:1259–1271. doi: 10.1056/NEJMoa2214403CrossrefGoogle Scholar2. Kobeissi H, Adusumilli G, Ghozy S, Kadirvel R, Brinjikji W, Albers GW, Heit JJ, Kallmes DF. Endovascular thrombectomy for ischemic stroke with large core volume: an updated, post-TESLA systematic review and meta-analysis of the randomized trials.Interv Neuroradiol. 2023;15910199231185738. doi: 10.1177/15910199231185738CrossrefGoogle Scholar3. Huo X, Ma G, Tong X, Zhang X, Pan Y, Nguyen TN, Yuan G, Han H, Chen W, Wei M, et al; ANGEL-ASPECT Investigators. Trial of endovascular therapy for acute ischemic stroke with large infarct.N Engl J Med. 2023; 388:1272–1283. doi: 10.1056/NEJMoa2213379CrossrefGoogle Scholar4. Samuels N, van de Graaf RA, Mulder MJHL, Brown S, Roozenbeek B, van Doormaal PJ, Goyal M, Campbell BCV, Muir KW, Agrinier N, et al; HERMES Collaborators. Admission systolic blood pressure and effect of endovascular treatment in patients with ischaemic stroke: an individual patient data meta-analysis.Lancet Neurol. 2023; 22:312–319. doi: 10.1016/S1474-4422(23)00076-5CrossrefGoogle Scholar5. Yang P, Song L, Zhang Y, Zhang X, Chen X, Li Y, Sun L, Wan Y, Billot L, Li Q, et al; ENCHANTED2/MT Investigators. Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): a multicentre, open-label, blinded-endpoint, randomised controlled trial.Lancet. 2022; 400:1585–1596. doi: 10.1016/S0140-6736(22)01882-7CrossrefGoogle Scholar6. Mistry E, Hart K, Davis L, et al. Blood Pressure After Endovascular Stroke Treatment (BEST)-II: a randomized clinical trial. In: Late Breaking Abstract 18-International Stroke Conference; 2023.Google Scholar7. Lowering blood pressure after clot removal may not be safe; should be individualized.American Heart Association. https://newsroom.heart.org/news/lowering-blood-pressure-after-clot-removal-may-not-be-safe-should-be-individualizedGoogle Scholar8. Piller C. Report on trial death stokes Alzheimer's drug fears.Science. 2023; 380:122–123. doi: 10.1126/science.adi2242CrossrefGoogle Scholar9. Will unpredictable side effects dim the promise of new Alzheimer's drugs?Science. AAAS https://www.science.org/content/article/will-unpredictable-side-effects-dim-promise-new-alzheimer-s-drugsGoogle Scholar10. Hoh BL, Ko NU, Amin-Hanjani S, Chou SHY, Cruz-Flores S, Dangayach NS, Derdeyn CP, Du R, Hänggi D, Hetts SW, et al. 2023 Guideline for the management of patients with aneurysmal subarachnoid hemorrhage: a guideline from the American Heart Association/American Stroke Association.Stroke. 2023; 54:e314–e370. doi: 10.1161/STR.0000000000000436LinkGoogle Scholar11. Treggiari MM, Rabinstein AA, Busl KM, Caylor MM, Citerio G, Deem S, Diringer M, Fox E, Livesay S, Sheth KN, et al. Guidelines for the neurocritical care management of aneurysmal subarachnoid hemorrhage.Neurocrit Care. 2023; doi: 10.1007/s12028-023-01713-5CrossrefGoogle Scholar12. Yoshimura S, Sakai N, Yamagami H, Uchida K, Beppu M, Toyoda K, Matsumaru Y, Matsumoto Y, Kimura K, Takeuchi M, et al. Endovascular therapy for acute stroke with a large ischemic region.N Engl J Med. 2022; 386:1303–1313. doi: 10.1056/NEJMoa2118191CrossrefGoogle Scholar13. Uchida K, Shindo S, Yoshimura S, Toyoda K, Sakai N, Yamagami H, Matsumaru Y, Matsumoto Y, Kimura K, Ishikura R, et al; RESCUE-Japan LIMIT Investigators. Association between Alberta stroke program early computed tomography score and efficacy and safety outcomes with endovascular therapy in patients with stroke from large-vessel occlusion: a secondary analysis of the Recovery by Endovascular Salvage for Cerebral Ultra-Acute Embolism-Japan Large Ischemic Core Trial (RESCUE-Japan LIMIT).JAMA Neurol. 2022; 79:1260–1266. doi: 10.1001/jamaneurol.2022.3285CrossrefGoogle Scholar14. Zaidat O, Yoo A, presenting authors. ESOC 2023 – late breaking abstracts: Thrombectomy for Emergent Salvage of Large Anterior Circulation Ischemic Stroke (TESLA).European Stroke Journal. 2023; 8:670–711.Google Scholar15. Costalat V, Lapergue B, Albucher JF, Labreuche J, Henon H, Gory B, Sibon I, Boulouis G, Cognard C, Nouri N, et al. EXPRESS: evaluation of acute mechanical revascularization in large stroke (ASPECT score ≤5) and large vessel occlusion within 7 hours of last-seen-well: the LASTE multicenter, randomized, clinical trial protocol.Int J Stroke. 2023; 98:e291–e301.Google Scholar16. Katsanos AH, Malhotra K, Ahmed N, Seitidis G, Mistry EA, Mavridis D, Kim JT, Veroniki AA, Maier I, Matusevicius M, et al. Blood pressure after endovascular thrombectomy and outcomes in patients with acute ischemic stroke: an individual patient data aeta-analysis.Neurology. 2022; 98:e291–e301. doi: 10.1212/WNL.0000000000013049CrossrefGoogle Scholar17. Jha RM, Sheth KN. Neurocritical care updates in cerebrovascular disease.Stroke. 2022; 53:2954–2957. doi: 10.1161/STROKEAHA.122.038881LinkGoogle Scholar18. Predilla G, presenting author. (PS1) late-breaking abstract presentation: Efficacy and Safety of Early Minimally Invasive Removal of Intracerebral Hemorrhage (ENRICH): a multi-centered randomized adaptive trial.AANS. 2023Plenary Session. https://2023aansannualmeeting.eventscribe.net/fsPopup.asp?efp=QkJBUkFWVkQxNTIwMA&PresentationID=1237542&rnd=0.50972&mode=presInfoGoogle Scholar19. Ma L, Hu X, Song L, Chen X, Ouyang M, Billot L, Li Q, Malavera A, Li X, Muñoz-Venturelli P, et al; INTERACT3 Investigators. The Third Intensive Care Bundle With Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial.Lancet. 2023; 402:27–40. doi: 10.1016/S0140-6736(23)00806-1CrossrefGoogle Scholar20. Shah VA, Thompson RE, Yenokyan G, Acosta JN, Avadhani R, Dlugash R, McBee N, Li Y, Hansen BM, Ullman N, et al. One-year outcome trajectories and factors associated with functional recovery among survivors of intracerebral and intraventricular hemorrhage with initial severe disability.JAMA Neurol. 2022; 79:856–868. doi: 10.1001/jamaneurol.2022.1991CrossrefGoogle Scholar21. Peter-Derex L, Philippeau F, Garnier P, André-Obadia N, Boulogne S, Catenoix H, Convers P, Mazzola L, Gouttard M, Esteban M, et al. Safety and Efficacy of Prophylactic Levetiracetam for Prevention of Epileptic Seizures in the Acute Phase of Intracerebral Haemorrhage (PEACH): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Neurol. 2022; 21:781–791. doi: 10.1016/S1474-4422(22)00235-6CrossrefGoogle Scholar22. Jeong SY, Suh CH, Shim WH, Lim JS, Lee JH, Kim SJ. Incidence of amyloid-related imaging abnormalities in patients with Alzheimer disease treated with anti-β-amyloid immunotherapy: a meta-analysis.Neurology. 2022; 99:e2092–e2101. doi: 10.1212/WNL.0000000000201019CrossrefGoogle Scholar23. Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, Suhy J, Forrestal F, Tian Y, Umans K, et al. Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease.JAMA Neurol. 2022; 79:13–21. doi: 10.1001/jamaneurol.2021.4161CrossrefGoogle Scholar24. Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, Atri A. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics.Brain. 2023;awad188. doi: 10.1093/brain/awad188CrossrefGoogle Scholar25. Barakos J, Purcell D, Suhy J, Chalkias S, Burkett P, Marsica Grassi C, Castrillo-Viguera C, Rubino I, Vijverberg E. Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with anti-amyloid beta therapy.J Prev Alzheimers Dis. 2022; 9:211–220. doi: 10.14283/jpad.2022.21CrossrefGoogle Scholar26. Filippi M, Cecchetti G, Spinelli EG, Vezzulli P, Falini A, Agosta F. Amyloid-related imaging abnormalities and β-amyloid-targeting antibodies: a systematic review.JAMA Neurol. 2022; 79:291–304. doi: 10.1001/jamaneurol.2021.5205CrossrefGoogle Scholar27. Villain N, Planche V, Levy R. High-clearance anti-amyloid immunotherapies in Alzheimer's disease part 1: meta-analysis and review of efficacy and safety data, and medico-economical aspects.Rev Neurol. 2022; 178:1011–1030. doi: 10.1016/j.neurol.2022.06.012CrossrefGoogle Scholar28. Jha RM, Rani A, Desai SM, Raikwar S, Mihaljevic S, Munoz-Casabella A, Kochanek PM, Catapano J, Winkler E, Citerio G, et al, Sulfonylurea receptor 1 in central nervous system injury: an updated review.Int J Mol Sci. 2021; 22:11899. doi: 10.3390/ijms222111899CrossrefGoogle Scholar29. Simard JM, Kent TA, Chen M, Tarasov KV, Gerzanich V. Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications.Lancet Neurol. 2007; 6:258–268. doi: 10.1016/S1474-4422(07)70055-8CrossrefMedlineGoogle Scholar30. Wolf S, Mielke D, Barner C, Malinova V, Kerz T, Wostrack M, Czorlich P, Salih F, Engel DC, Ehlert A, et al; EARLYDRAIN Study Group. Effectiveness of lumbar cerebrospinal fluid drain among patients with aneurysmal subarachnoid hemorrhage: a randomized clinical trial.JAMA Neurol. 2023; 80:833. doi: 10.1001/jamaneurol.2023.1792CrossrefGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetails October 2023Vol 54, Issue 10 Advertisement Article InformationMetrics © 2023 American Heart Association, Inc.https://doi.org/10.1161/STROKEAHA.123.043018PMID: 37747966 Originally publishedSeptember 25, 2023 Keywordsblood pressurestrokeedemadrug approvalcritical carePDF download Advertisement SubjectsCerebrovascular Disease/Stroke